Literature DB >> 24155248

Premenopausal serum sex hormone levels in relation to breast cancer risk, overall and by hormone receptor status - results from the EPIC cohort.

Rudolf Kaaks1, Kaja Tikk, Disorn Sookthai, Helena Schock, Theron Johnson, Anne Tjønneland, Anja Olsen, Kim Overvad, Françoise Clavel-Chapelon, Laure Dossus, Laura Baglietto, Sabina Rinaldi, Veronique Chajes, Isabelle Romieu, Heiner Boeing, Madlen Schütze, Antonia Trichopoulou, Pagona Lagiou, Dimitrios Trichopoulos, Domenico Palli, Sabina Sieri, Rosario Tumino, Fulvio Ricceri, Amalia Mattiello, Genevieve Buckland, Jose Ramón Quirós, María-José Sánchez, Pilar Amiano, Maria-Dolores Chirlaque, Aurelio Barricarte, H Bas Bueno-de-Mesquita, Carla H van Gils, Petra H Peeters, Anne Andersson, Malin Sund, Elisabete Weiderpass, Kay-Tee Khaw, Nick Wareham, Timothy J Key, Ruth C Travis, Melissa A Merritt, Marc J Gunter, Elio Riboli, Annekatrin Lukanova.   

Abstract

Results from prospective studies on premenopausal serum hormone levels in relation to breast cancer risk have been inconclusive, especially with regard to tumor subtypes. Using a case-control study nested within the prospective European Prospective Investigation into Cancer and Nutrition (EPIC) cohort (801 breast cancer cases and 1,132 matched control subjects), we analyzed the relationships of prediagnostic serum estradiol, free estradiol, progesterone, testosterone, free testosterone and sex hormone-binding globulin (SHBG) levels with the risk of breast cancer by estrogen and progesterone receptor-positive and -negative breast tumors and by age at diagnoses. Higher prediagnostic serum levels of testosterone and free testosterone were associated with an increased overall risk of breast cancer [ORQ4-Q1  = 1.56 (95% CI 1.15-2.13), ptrend  = 0.02 for testosterone and ORQ4-Q1  = 1.33 (95% CI 0.99-1.79), ptrend  = 0.04 for free testosterone], but no significant risk association was observed for estradiol, free estradiol, progesterone and SHBG. Tests for heterogeneity between receptor-positive and -negative tumors were not significant. When analysis were stratified by age at tumor diagnosis, the odds ratios observed for estradiol were stronger and borderline significant for breast cancer diagnosed at age less than 50 [ORQ4-Q1  = 1.32 (95% CI 0.87-2.01), ptrend  = 0.05] compared to breast cancer diagnosed at age 50 or above [ORQ4-Q1  = 0.94 (95% CI 0.60-1.47), ptrend  = 0.34, phet  = 0.04]. In conclusion, our data indicate that higher premenopausal circulating testosterone levels are associated with an increased risk of developing breast cancer, but do not show a significant association of estradiol or progesterone with breast cancer risk, overall, by menstrual cycle phase or by tumor receptor status, although a possible risk increase with higher estradiol levels for tumors diagnosed before age 50 was seen.
© 2013 UICC.

Entities:  

Keywords:  EPIC; breast cancer; estrogen receptor; prospective cohort; sex hormones

Mesh:

Substances:

Year:  2013        PMID: 24155248     DOI: 10.1002/ijc.28528

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  32 in total

1.  Mediation analysis of the alcohol-postmenopausal breast cancer relationship by sex hormones in the EPIC cohort.

Authors:  Nada Assi; Sabina Rinaldi; Vivian Viallon; S Ghazaleh Dashti; Laure Dossus; Agnès Fournier; Iris Cervenka; Marina Kvaskoff; Renée Turzanski-Fortner; Manuela Bergmann; Heiner Boeing; Salvatore Panico; Fulvio Ricceri; Domenico Palli; Rosario Tumino; Sara Grioni; María José Sánchez Pérez; María-Dolores Chirlaque; Catalina Bonet; Aurelio Barricarte Gurrea; Pilar Amiano Etxezarreta; Susana Merino; H Bas Bueno de Mesquita; Carla H van Gils; Charlotte Onland-Moret; Anne Tjønneland; Kim Overvad; Antonia Trichopoulou; Georgia Martimianaki; Anna Karakatsani; Tim Key; Sofia Christakoudi; Merete Ellingjord-Dale; Kostas Tsilidis; Elio Riboli; Rudolf Kaaks; Marc J Gunter; Pietro Ferrari
Journal:  Int J Cancer       Date:  2019-04-30       Impact factor: 7.396

2.  Nipple Aspirate Fluid Hormone Concentrations and Breast Cancer Risk.

Authors:  Robert T Chatterton; Richard E Heinz; Angela J Fought; David Ivancic; Claire Shappell; Subhashini Allu; Susan Gapstur; Denise M Scholtens; Peter H Gann; Seema A Khan
Journal:  Horm Cancer       Date:  2016-02-22       Impact factor: 3.869

3.  Circulating RANKL and RANKL/OPG and Breast Cancer Risk by ER and PR Subtype: Results from the EPIC Cohort.

Authors:  Danja Sarink; Helena Schock; Theron Johnson; Kim Overvad; Marianne Holm; Anne Tjønneland; Marie-Christine Boutron-Ruault; Mathilde His; Marina Kvaskoff; Heiner Boeing; Pagona Lagiou; Eleni-Maria Papatesta; Antonia Trichopoulou; Domenico Palli; Valeria Pala; Amalia Mattiello; Rosario Tumino; Carlotta Sacerdote; H B As Bueno-de-Mesquita; Carla H van Gils; Petra H Peeters; Elisabete Weiderpass; Antonio Agudo; Maria-José Sánchez; Maria-Dolores Chirlaque; Eva Ardanaz; Pilar Amiano; Kay Tee Khaw; Ruth Travis; Laure Dossus; Mark Gunter; Sabina Rinaldi; Melissa Merritt; Elio Riboli; Rudolf Kaaks; Renée T Fortner
Journal:  Cancer Prev Res (Phila)       Date:  2017-07-12

4.  Premenopausal Circulating Androgens and Risk of Endometrial Cancer: results of a Prospective Study.

Authors:  Tess V Clendenen; Kathryn Hertzmark; Karen L Koenig; Eva Lundin; Sabina Rinaldi; Theron Johnson; Vittorio Krogh; Göran Hallmans; Annika Idahl; Annekatrin Lukanova; Anne Zeleniuch-Jacquotte
Journal:  Horm Cancer       Date:  2016-02-29       Impact factor: 3.869

5.  Try113His and His139Arg polymorphisms in the microsomal epoxide hydrolase gene are not associated with risk of breast cancer.

Authors:  Wen-Feng Gong; Wen He; Qiu-Ming Zhang; Bang-De Xiang; Liang Ma; Shan Huang; Tao Bai; Jian-Hong Zhong; Le-Qun Li
Journal:  Tumour Biol       Date:  2014-05-20

6.  Dietary Patterns and Plasma Sex Hormones, Prolactin, and Sex Hormone-Binding Globulin in Premenopausal Women.

Authors:  Kelly A Hirko; Donna Spiegelman; Junaidah B Barnett; Eunyoung Cho; Walter C Willett; Susan E Hankinson; A Heather Eliassen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-03-15       Impact factor: 4.254

7.  Prediagnostic Sex Steroid Hormones in Relation to Male Breast Cancer Risk.

Authors:  Louise A Brinton; Tim J Key; Laurence N Kolonel; Karin B Michels; Howard D Sesso; Giske Ursin; Stephen K Van Den Eeden; Shannon N Wood; Roni T Falk; Dominick Parisi; Chantal Guillemette; Patrick Caron; Véronique Turcotte; Laurel A Habel; Claudine J Isaacs; Elio Riboli; Elisabete Weiderpass; Michael B Cook
Journal:  J Clin Oncol       Date:  2015-05-11       Impact factor: 44.544

8.  The relationship between bilateral oophorectomy and plasma hormone levels in postmenopausal women.

Authors:  Joanne Kotsopoulos; Amy L Shafrir; Megan Rice; Susan E Hankinson; A Heather Eliassen; Shelley S Tworoger; Steven A Narod
Journal:  Horm Cancer       Date:  2014-12-19       Impact factor: 3.869

Review 9.  Progesterone and Breast Cancer.

Authors:  Britton Trabert; Mark E Sherman; Nagarajan Kannan; Frank Z Stanczyk
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871

10.  Circulating Hormones and Mammographic Density in Premenopausal Women.

Authors:  Kimberly A Bertrand; A Heather Eliassen; Susan E Hankinson; Bernard A Rosner; Rulla M Tamimi
Journal:  Horm Cancer       Date:  2018-01-12       Impact factor: 3.869

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.